Immunome IMNM Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$53.84M+23.0% | -$69.9M-21.7% | -$57.46M-32.4% | -$43.4M-4.2% | -$41.64M+48.1% | ||
| $603K-4.1% | $629K+6.8% | $589K-7.5% | $637K+4.3% | $611K+35.8% | ||
| $7.95M+0.8% | $7.89M+17.0% | $6.75M+26.2% | $5.35M-6.2% | $5.7M+4.3% | ||
| -$79K-43.6% | -$55K— | $0+100% | -$891K— | -$0— | ||
| $1.42M+162% | -$2.28M— | —— | -$4.95M-29.9% | -$3.81M-141% | ||
| $5.1M+12,038% | $42K— | —— | $3.6M+111% | $1.71M— | ||
| -$0— | —— | —— | -$4.02M-37.2% | -$2.93M-6.9% | ||
| $150K+2.0% | $147K+2.1% | $144K+73.5% | $83K-27.8% | $115K-20.7% | ||
| -$161K-1.9% | -$158K-22.5% | -$129K-170% | $183K+395% | -$62K— | ||
| -$58.64M-22.3% | -$47.95M-18.4% | -$40.51M+18.0% | -$49.4M+6.9% | -$53.06M-26.1% | ||
| $3M-24.9% | $4M+258% | $1.12M+23.3% | $905K-75.3% | $3.67M+225% | ||
| —— | —— | —— | —— | —— | ||
| $0— | $0-100% | $125M+108% | $60M+300% | $15M-82.4% | ||
| $9.01M— | —— | —— | —— | $6.25M+2,408% | ||
| -$12.02M— | $0-100% | $123.88M+293% | -$64.17M-1,361% | $5.09M— | ||
| $229K— | $0-100% | $45.47M+21,048% | $215K+0.9% | $213K-98.9% | ||
| -$135K-100% | $432.8M+854% | $45.39M— | $0-100% | $162.23M+708% | ||
| -$70.79M-119% | $380.84M+196% | $128.76M— | —— | $114.26M— | ||
| $0— | $0-100% | $816K-32.3% | $1.21M+47.3% | $818K+52.6% | ||
| —— | $2.5M0.0% | $2.5M0.0% | $2.5M0.0% | $2.5M-93.4% | ||
| -$9.75M-271% | $5.7M— | —— | —— | -$8.52M-19,916% | ||
| -$161K-1.9% | -$158K-22.5% | -$129K-170% | $183K+395% | -$62K— | ||
| $5.1M+12,038% | $42K— | —— | $3.6M+111% | $1.71M— | ||
| $150K+2.0% | $147K+2.1% | $144K+73.5% | $83K-27.8% | $115K-20.7% | ||
| $9.01M— | —— | —— | —— | $6.25M+2,408% | ||
| $0— | $0-100% | $125M+108% | $60M+300% | $15M-82.4% | ||
| $364K-98.7% | $27.78M+2,923% | $919K+240% | $270K-97.4% | $10.49M+2,521% | ||
| $0-100% | $460.5M— | —— | —— | $172.5M— | ||
| —— | $0— | $0— | —— | —— | ||
| $1.13M— | —— | —— | $695K+17.4% | $592K-73.9% | ||
| -$0— | —— | —— | -$4.02M-37.2% | -$2.93M-6.9% | ||
| -$161K-1.9% | -$158K-22.5% | -$129K-170% | $183K+395% | -$62K— | ||
| —— | $0— | $0— | —— | —— | ||
| $0— | —— | —— | -$270K-200% | $270K— | ||
| $986K— | —— | —— | —— | $0-100% | ||
| —— | $0— | $0— | —— | —— | ||
| -$61.64M-18.6% | -$51.95M-24.8% | -$41.63M+17.3% | -$50.31M+11.3% | -$56.72M-31.3% | ||
| -$61.64M-18.6% | -$51.95M-24.8% | -$41.63M+17.3% | -$50.31M+11.3% | -$56.72M-31.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Immunome's cash flow data come from?
- Every line is extracted from Immunome's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.